что приготовить на праздничный стол для детей 2 лет
Главное меню:
Интересное
что приготовить на праздничный стол для детей 2 лет, Lung Cancer - Medscape, Small Cell Lung Cancer in 2024: Treatment Advances - Medscape, Two Lung Cancer Drugs Recommended by EMA - Medscape, Advanced Non-Small Cell Lung Cancer Updates From ASCO 2024 - Medscape, A ‘Fool’s Errand’? Picking a Winner for Treating Early NSCLC, Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung , Zenocutuzumab Effective Against NRG1 Fusion Cancers - Medscape.
COMMENTARYSmall Cell Lung Cancer in 2024: Treatment AdvancesMark G. Kris, MD | March 19, 2025 0This transcript has been edited for clarity. This is Mark Kris, going over developments in small cell lung cancer in 2024 that have advanced therapy in the field. I think the most dramatic one is the long overdue emergence of checkpoint inhibitors. With following concurrent chemotherapy and radiation for limited-stage small cell lung cancer showing clear benefits in extensive stage disease, it seems to me we're going to see the same benefits with limited stage disease. In the reported this year, there was a near doubling of overall survival, from 33 to 66 months, by the addition of after concurrent chemotherapy and radiation in limited-stage small cell lung cancer. I think that is now our new standard of care.Complicating things, though, are the data. Looking at in limited-stage patients, . This raises the question of: Which drug do you use? You have every reason to think that would be as effective as durvalumab.Clearly, both drugs have been shown to be effective in extensive-stage patients and are standards of care. However, we have conflicting data. I think we know what to do with our patients in this situation, but we don't quite know how to process the data from atezolizumab. It's been presented, but more data are going to come out to help us understand that.Another and more difficult decision for us is the appearance of . This is our first bispecific T-cell engager for the treatment of lung cancers. I think people have seen from this agent. There is a 40% major response rate. Those responses are generally meaningful for the patients. They're durable — more than half of the responses last 6 months, about a quarter last more than 9 months, and they're clearly important. However, there are other drugs available in this area. Many chemotherapy drugs have activity, and depending on how long after the initial benefit the recurrence occurs, our go-to is to repeat the standard drugs we started at, either or and . The benefits there are usually very evident, and the greater the time from the conclusion of initial therapy to the recurrence, the more likely it is to help.Balancing against the clear benefit of tarlatamab in 40% of patients and the long responses is the disease-free survival, which is less than 5 months. Balancing against the 40% response rate is the 50% incidence of . Again, many patients with recurrent, small cell lung cancer are not well. I think, particularly in those patients who have had the standard etoposide and platinum agents, this can be a tough decision on the appropriateness of those therapies [since] most institutions require hospitalization and [there is] also the adverse effects of therapy as well. Particularly in light of the other therapies available, repeating the initial therapy and other agents, when you look at the phase 2 activity of drugs second line for small cell [lung cancer], many drugs have activity in the 20%-40% range. Exactly how much additional benefit comes from a drug like tarlatamab is something that we're going to have to figure out as time goes on. There are no randomized data at this point. This is another tough decision for doctors. For patients, this is another therapy that can be helpful, but which patients are the right ones? Should tarlatamab be the second treatment or maybe the third? That's a tough decision and it's one we're going to have to make.In 2024 for small cell [lung cancer], there’s a clear benefit of durvalumab in limited-stage disease. Tarlatamab is another drug that can provide benefit to our patients, but how to choose patients, particularly for the tarlatamab, is another tough decision point for us. Again, you have to enlist the patient as to what their expectations are and what degree of adverse effects they would be willing to face to achieve that benefit, which frankly, doesn't affect the majority of patients.That's a tough decision, and one that we're going to have to make. We're going to have to explain and work through our discussions with patients in order to decide if it represents the best therapy.0 Medscape Oncology © 2025 WebMD, LLCAny views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape. Cite this: Small Cell Lung Cancer in 2024: Treatment Advances - Medscape - March 19, 2025. Comments Commenting is limited to medical professionals. To comment please . Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.TOP PICKS FOR YOURecommendationsWhat to Read Next on MedscapeBusiness of MedicineRecommended ReadingDiseases & ConditionsNon-Small Cell Lung Cancer (NSCLC) StagingDiseases & ConditionsSmall Cell Lung Cancer (SCLC)Diseases & ConditionsNon-Small Cell Lung Cancer (NSCLC)Diseases & ConditionsSmall Cell Lung Cancer (SCLC) ImagingRelated Conditions & ProceduresSlideshowExpert CommentaryPoliciesMedscapeAboutFor Advertisers GET THE MEDSCAPE APP All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties., Lung Cancer : Review in-depth clinical information, latest medical news, and guidelines on lung cancer, specifically small-cell lung cancer and non-small-cell lung cancer. Read the latest , Amgen Drug Cuts Small Cell Lung Cancer Death Risk by 40%; Moving Earlier in the Disease Landscape: Understanding Adjuvant Immunotherapy for Non-Small Cell Lung Cancer 0.25 CME / ABIM MOC Credits.
Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer? Small Cell Lung Cancer in 2024: Treatment Advances 3090D553-9492-4563-8681-AD288FA52ACE, Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, including the phase 3 LAURA and PALOMA-3 studies and a 5-year update of CROWN., Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer? Small Cell Lung Cancer in 2024: Treatment Advances 3090D553-9492-4563-8681-AD288FA52ACE, Dr Narjust Florez explores the transformative shifts in the treatment landscape for early-stage non–small cell lung cancer over the years, particularly emphasizing the significant changes , The bispecific antibody shows particularly promising results in non–small cell lung cancer (NSCLC) and pancreatic cancer patients, with responses lasting a median of 11.1 months., Non-Small Cell Lung Cancer (NSCLC) Imaging; Evolving Treatment for Small Cell Lung Cancer; Multidisciplinary Management of Stage III Lung Cancer; SLIDESHOW. Brain Lesions: Summaries of 12 Cases;.